Low frequency of pendrin autoantibodies detected using a radioligand binding assay in patients with autoimmune thyroid disease

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages

  Kemp, E Helen ^a   Sandhu, Harpreet K ^a   Watson, Philip F ^a   Weetman, Anthony P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PENDRIN; RADIOLIGAND;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNE THYROIDITIS; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOREACTIVITY; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RADIOFREQUENCY; RELIABILITY;

ADULT; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; THYROIDITIS, AUTOIMMUNE;

EID: 84873623666     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3683     Document Type: Article

References (17)

1. Weetman AP. Graves' disease. NEng J Med. 2000;343:1236-1248.
2. - cotransporter as a potential autoantigen in thyroid autoimmune disease. Eur J Endocrinol. 1995;132:399-405.
3. Royaux IE, Suzuki K, Mori A, et al. Pendrin, the protein encoded by the pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. Endocrinology. 2000;141:839-845.
4. Scott DA, Wang R, Kreman TM, Sheffield VC, Karniski LP. The pendred syndrome encodes a chloride-iodide transport protein. Nat Genet. 1999;21:440-443.
5. Everett LA, Glaser B, Beck JC, et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet. 1997;17:411-422.
6. Kopp P. Pendred's syndrome: identification of the genetic defect a century after its recognition. Thyroid. 1999;9:65-69.
7. Yoshida A, Hisatome I, Taniguchi S, et al. Pendrin is a novel autoantigen recognised by patients with autoimmune thyroid diseases. J Clin Endrinol Metab. 2009;94:442-448.
8. Van Dam AP, Van den Brink HG, Smeenk RJ. Technical problems concerning the use of immunoblots for the detection of antinuclear antibodies. J Immunol Methods. 1990;129:63-70.
9. Belguith-Maalej S, Hadj-Kacem H, Rebuffat SA, et al. Absence of anti-pendrin auto-antibodies in the sera of Tunisian patients with autoimmune thyroid diseases. Clin Lab. 2010;56:335-343.
10. Tiberti C, Yu L, Lucantoni F, et al. Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative highthroughput approach for autoimmune diabetes screening. Clin Exp Immunol. 2011;166:317-324.
11. Husebye ES, Gebre-Medhin G, Tuomi T, et al. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 1997;82:147-150.
12. Peterson P, Uibo R, Peränen J, Krohn K. Immunoprecipitation of steroidogenic enzyme autoantigens with autoimmune polyglandular syndrome type I (APS I) sera: further evidence for independent humoral immunity to P450c17 and P450c21. Clin Exp Immunol. 1997;107:335-340.
13. Satoh M, Ajmani AK, Ogasawara T, et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest. 1994;94:1981-1989.
14. Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. ArthritisRheum. 2003;48:1363-1373.
15. Kemp EH, Gawkrodger DJ, MacNeil S, Watson PF, Weetman AP. Detection of tyrosinase autoantibodies in the sera of vitiligo patients using 35S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol. 1997;109:69-73.
16. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol. 1997;109:495-500.
17. Kemp EH, Waterman EA, Hawes BE, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest. 2002;109:923-930.